RecruitingNCT05052671
ctDNA Assay in Patients With Resectable Pancreatic Cancer
Application of ctDNA Assay in the Neoadjuvant and Adjuvant Chemotherapy Setting in Patients With Resectable Pancreatic Cancer
Sponsor
University of Oklahoma
Enrollment
50 participants
Start Date
May 25, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may provide preliminary evidence that helps improve future patient care through targeted diagnostics, prognosis, and/or treatment.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria7
- Newly diagnosed exocrine pancreatic cancer with either pathology or radiology imaging suggestive of adenocarcinoma
- Resectable/Borderline Resectable Pancreatic cancer as defined by the NCCN guidelines
- ≥ 18 years old at the time of informed consent
- ECOG Performance Status 0 or 1
- Patients who are candidates for neoadjuvant chemo/chemoradiotherapy or upfront surgery are eligible for the study.
- Ability to provide written informed consent and HIPAA authorization
- Patients must have a life expectancy of at least 6 months
Exclusion Criteria4
- Patients with pancreatic malignant tumor histologically confirmed as neuroendocrine or any other type of malignancies
- Positive pregnancy test, pregnant, or breastfeeding
- Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study
- Locally advanced or metastatic disease
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05052671
Related Trials
Autologous CAR-T Cells Targeting B7-H3 in PDAC
NCT061581391 location
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Reinforced Pancreaticojejunostomy With or Without glubran2
NCT067560741 location
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
NCT064792391 location
Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts
NCT044737941 location